You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMirtazapine
Accession NumberDB00370  (APRD00685)
TypeSmall Molecule
GroupsApproved
Description

Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia]

Structure
Thumb
Synonyms
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
6-Azamianserin
Mepirzapine
Mirtazapin
Mirtazapina
Mirtazapine
Mirtazapinum
External Identifiers
  • Org 3770
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-mirtazapinetablet45 mgoralAuro Pharma Inc2013-10-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-mirtazapinetablet30 mgoralAuro Pharma Inc2013-10-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-mirtazapinetablet15 mgoralAuro Pharma Inc2013-10-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-mirtazapine ODtablet (orally disintegrating)45 mgoralAuro Pharma Inc2010-12-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-mirtazapine ODtablet (orally disintegrating)30 mgoralAuro Pharma Inc2010-12-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-mirtazapine ODtablet (orally disintegrating)15 mgoralAuro Pharma Inc2010-12-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ava-mirtazapinetablet30 mgoralAvanstra Inc2011-08-182014-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ava-mirtazapinetablet15 mgoralAvanstra Inc2011-08-182014-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Co Mirtazapinetablet30 mgoralCobalt Pharmaceuticals Company2006-03-232013-07-19Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-mirtazapinetablet15 mgoralDominion Pharmacal2006-08-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-mirtazapinetablet30 mgoralDominion Pharmacal2004-05-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gd-mirtazapine ODtablet (orally disintegrating)30 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-042014-12-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gd-mirtazapine ODtablet (orally disintegrating)15 mgoralGenmed A Division Of Pfizer Canada Inc2012-04-262014-12-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gd-mirtazapine ODtablet (orally disintegrating)45 mgoralGenmed A Division Of Pfizer Canada Inc2012-04-262014-12-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-mirtazapinetablet15 mgoralJamp Pharma Corporation2011-10-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-mirtazapinetablet30 mgoralJamp Pharma Corporation2011-10-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapinetablet, orally disintegrating45 mg/1oralPhysicians Total Care, Inc.2012-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mgoralMeliapharm Inc2004-04-142014-06-25Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapinetablet, orally disintegrating45 mg/1oralPrasco Laboratories2001-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mgoralMeliapharm Inc2006-07-212014-06-25Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapinetablet30 mgoralSanis Health Inc2011-09-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapinetablet, orally disintegrating30 mg/1oralPrasco Laboratories2001-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2001-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapine - 15tablet15 mgoralPro Doc Limitee2007-10-262008-07-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapine - 30tablet30 mgoralPro Doc Limitee2007-10-262008-07-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapine - 45tablet45 mgoralPro Doc Limitee2007-10-262009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-mirtazapinetablet45 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-mirtazapinetablet30 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-mirtazapinetablet15 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-mirtazapinetablet30 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)45 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)30 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)15 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-mirtazapinetablet45 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-mirtazapinetablet30 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-mirtazapinetablet15 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-mirtazapinetablet15 mgoralPharmascience Inc2005-11-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-mirtazapinetablet30 mgoralPharmascience Inc2004-01-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pro-mirtazapinetablet30 mgoralPro Doc Limitee2008-07-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pro-mirtazapinetablet15 mgoralPro Doc Limitee2008-07-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-mirtazapinetablet30 mgoralRatiopharm Inc Division Of Teva Canada Limited2005-09-292014-09-19Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Remerontablet, film coated15 mg/1oralOrganon USA Inc.1996-06-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Remerontablet, film coated15 mg/1oralPhysicians Total Care, Inc.2001-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Remerontablet, film coated45 mg/1oralOrganon USA Inc.1997-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Remerontablet30 mgoralMerck Canada Inc2001-05-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Remerontablet, film coated30 mg/1oralOrganon USA Inc.1996-06-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Remeron Rdtablet (orally disintegrating)45 mgoralMerck Canada Inc2003-12-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Remeron Rdtablet (orally disintegrating)30 mgoralMerck Canada Inc2003-12-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Remeron Rdtablet (orally disintegrating)15 mgoralMerck Canada Inc2003-12-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Remeronsoltabtablet, orally disintegrating45 mg/1oralOrganon USA Inc.2001-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Remeronsoltabtablet, orally disintegrating30 mg/1oralOrganon USA Inc.2001-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Remeronsoltabtablet, orally disintegrating15 mg/1oralOrganon USA Inc.2001-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Riva-mirtazapinetablet30 mgoralLaboratoire Riva Inc2005-03-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Mirtazapinetablet30 mgoralSandoz Canada Incorporated2004-03-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Mirtazapinetablet15 mgoralSandoz Canada Incorporated2004-03-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Mirtazapine Fctablet30 mgoralSandoz Canada Incorporated2005-05-092009-08-06Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-mirtazapinetablet30 mgoralTeva Canada Limited2005-10-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-mirtazapine ODtablet (orally disintegrating)45 mgoralTeva Canada Limited2006-08-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-mirtazapine ODtablet (orally disintegrating)30 mgoralTeva Canada Limited2006-08-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-mirtazapine ODtablet (orally disintegrating)15 mgoralTeva Canada Limited2006-08-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Zym-mirtazapinetablet15 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Zym-mirtazapinetablet30 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mirtazapinetablet30 mgoralApotex Inc2006-10-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-mirtazapinetablet15 mgoralApotex Inc2006-10-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-mirtazapinetablet45 mgoralApotex Inc2006-10-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mirtazapinetablet, film coated15 mg/1oralAidarex Pharmaceuticals LLC2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralCardinal Health2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralAmerican Health Packaging2005-12-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-08-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating15 mg/1oralActavis Pharma, Inc.2014-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2003-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating15 mg/1oralCitron Pharma LLC2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2012-09-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralCardinal Health2009-11-302015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating15 mg/1oralAurobindo Pharma Limited2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated7.5 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralKAISER FOUNDATION HOSPITALS2010-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralPd Rx Pharmaceuticals, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralREMEDYREPACK INC.2013-03-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating30 mg/1oralbryant ranch prepack2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralRebel Distributors Corp.2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralActavis Pharma, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralApotex Corp.2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2003-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2012-03-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralCardinal Health2009-11-302015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2003-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralKAISER FOUNDATION HOSPITALS2011-05-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralRebel Distributors Corp2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating15 mg/1oralbryant ranch prepack2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralSTAT Rx USA LLC2003-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralMylan Pharmaceuticals Inc.2012-12-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2010-11-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralClinical Solutions Wholesale2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralMylan Institutional Inc.2003-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralCardinal Health2004-04-222015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralProficient Rx LP2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated7.5 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating45 mg/1oralTeva Pharmaceuticals USA Inc2005-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralRebel Distributors Corp2003-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet7.5 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralbryant ranch prepack2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralSTAT Rx USA LLC2003-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralMylan Pharmaceuticals Inc.2012-12-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2010-09-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralClinical Solutions Wholesale2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralCardinal Health2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralMylan Institutional Inc.2003-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralCardinal Health2004-04-222015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralTYA Pharmaceuticals2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating30 mg/1oralTeva Pharmaceuticals USA Inc2005-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralRebel Distributors Corp2003-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralSTAT Rx USA LLC2003-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralMylan Pharmaceuticals Inc.2012-12-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralMedsource Pharmaceuticals2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralClinical Solutions Wholesale2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralCardinal Health2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralMylan Institutional Inc.2003-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralbryant ranch prepack2003-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralTYA Pharmaceuticals2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating15 mg/1oralTeva Pharmaceuticals USA Inc2005-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated7.5 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2011-07-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralMc Kesson Contract Packaging2012-01-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralEon Labs, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralClinical Solutions Wholesale, Llc2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralPhysicians Total Care, Inc.2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralUnit Dose Services2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralbryant ranch prepack2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating45 mg/1oralActavis Pharma, Inc.2014-11-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralTeva Pharmaceuticals USA Inc2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated7.5 mg/1oralCardinal Health2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2011-07-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralMc Kesson Contract Packaging2011-10-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralTYA Pharmaceuticals2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating45 mg/1oralCitron Pharma LLC2006-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralPhysicians Total Care, Inc.2006-07-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating45 mg/1oralAurobindo Pharma Limited2006-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralEon Labs, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralApotex Corp.2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralH.J. Harkins Company, Inc.2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating45 mg/1oralbryant ranch prepack2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralAmerican Health Packaging2005-10-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralRebel Distributors Corp.2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralActavis Pharma, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-07-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralAidarex Pharmaceuticals LLC2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralCardinal Health2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-07-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-09-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating30 mg/1oralActavis Pharma, Inc.2014-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralTeva Pharmaceuticals USA Inc2003-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating30 mg/1oralCitron Pharma LLC2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet30 mg/1oralPhysicians Total Care, Inc.2005-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralMajor Pharmaceuticals2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated45 mg/1oralProficient Rx LP2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating30 mg/1oralAurobindo Pharma Limited2005-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralEon Labs, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralApotex Corp.2007-08-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralCardinal Health2003-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, orally disintegrating45 mg/1oralbryant ranch prepack2006-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated15 mg/1oralAmerican Health Packaging2005-10-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralRebel Distributors Corp.2004-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet, film coated30 mg/1oralActavis Pharma, Inc.2003-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AvanzaSchering-Plough
AxitAlphapharm
Mirtabeneratiopharm
MirtazPinewood
MirtazonSchering-Plough
NorsetMSD France
PromyrtilSchering-Plough
RemergilMerck Sharp & Dohme
RemergonOrganon
Remeron SolTabNot Available
RexerSchering-Plough
ZispinOrganon
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIA051Q2099Q
CAS number61337-67-5
WeightAverage: 265.3529
Monoisotopic: 265.157897623
Chemical FormulaC17H19N3
InChI KeyInChIKey=RONZAEMNMFQXRA-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
IUPAC Name
5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene
SMILES
CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as piperazinoazepines. These are compounds containing a piperazinoazepine skeleton, which consists of an azepie ring fused to a piperazine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperazinoazepines
Sub ClassNot Available
Direct ParentPiperazinoazepines
Alternative Parents
Substituents
  • Piperazino-azepine
  • Benzazepine
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Azepine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of major depressive disorder.
PharmacodynamicsMirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.
Mechanism of actionMirtazapine acts as an antagonist at central pre-synaptic alpha(2)-receptors, inhibiting negative feedback to the presynaptic nerve and causing an increase in NE release. Blockade of heteroreceptors, alpha(2)-receptors contained in serotenergic neurons, enhances the release of 5-HT, increasing the interactions between 5-HT and 5-HT1 receptors and contributing to the anxiolytic effects of mirtazapine. Mirtazapine also acts as a weak antagonist at 5-HT1 receptors and as a potent antagonist at 5-HT2 (particularly subtypes 2A and 2C) and 5-HT3 receptors. Blockade of these receptors may explain the lower incidence of adverse effects such as anxiety, insomnia, and nausea. Mirtazapine also exhibits significant antagonism at H1-receptors, resulting in sedation. Mirtazapine has no effects on the reuptake of either NE or 5-HT and has only minimal activity at dopaminergic and muscarinic receptors.
AbsorptionRapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.
Volume of distributionNot Available
Protein binding85%
Metabolism

Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.

SubstrateEnzymesProduct
Mirtazapine
mirtazapine-N-oxideDetails
Mirtazapine
N-desmethylmirtazapineDetails
Mirtazapine
8-hydroxymirtazapineDetails
Route of eliminationThis drug is known to be substantially excreted by the kidney (75%).
Half life20-40 hours
ClearanceNot Available
ToxicitySymptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50 is 600-720mg/kg (oral, mice) and 320-490mg/kg (oral, rat) [PMID: 10333982]
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9873
Blood Brain Barrier+0.9855
Caco-2 permeable+0.7283
P-glycoprotein substrateSubstrate0.8462
P-glycoprotein inhibitor IInhibitor0.6148
P-glycoprotein inhibitor IINon-inhibitor0.8975
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.7988
CYP450 2D6 substrateSubstrate0.7894
CYP450 3A4 substrateNon-substrate0.5148
CYP450 1A2 substrateInhibitor0.8503
CYP450 2C9 inhibitorNon-inhibitor0.6675
CYP450 2D6 inhibitorInhibitor0.7222
CYP450 2C19 inhibitorNon-inhibitor0.6206
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6031
Ames testNon AMES toxic0.8079
CarcinogenicityNon-carcinogens0.9742
BiodegradationNot ready biodegradable0.9919
Rat acute toxicity2.5197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7532
hERG inhibition (predictor II)Inhibitor0.7455
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis totowa llc
  • Aurobindo pharma ltd inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Organon usa inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg/1
Tabletoral30 mg/1
Tabletoral45 mg/1
Tabletoral7.5 mg/1
Tablet, film coatedoral7.5 mg/1
Tabletoral45 mg
Tabletoral30 mg
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral45 mg/1
Tablet (orally disintegrating)oral15 mg
Tablet (orally disintegrating)oral30 mg
Tablet (orally disintegrating)oral45 mg
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral30 mg/1
Tablet, orally disintegratingoral45 mg/1
Tabletoral15 mg
Prices
Unit descriptionCostUnit
Remeron SolTab 30 45 mg Dispersible Tablet Box114.4USD box
Remeron SolTab 30 15 mg Dispersible Tablet Box107.58USD box
Remeron SolTab 30 30 mg Dispersible Tablet Box107.27USD box
Mirtazapine 30 45 mg Dispersible Tablet Box88.95USD box
Mirtazapine 30 30 mg Dispersible Tablet Box83.48USD box
Mirtazapine 30 15 mg Dispersible Tablet Box81.02USD box
Remeron 45 mg tablet4.61USD tablet
Remeron 15 mg tablet4.42USD tablet
Remeron 45 mg soltab3.57USD tablet
Remeron 30 mg soltab3.55USD tablet
Remeron 30 mg tablet3.47USD tablet
Remeron 15 mg soltab3.26USD tablet
Mirtazapine 45 mg tablet2.91USD tablet
Mirtazapine 30 mg tablet2.85USD tablet
Mirtazapine 15 mg tablet2.77USD tablet
Mirtazapine 7.5 mg tablet2.56USD tablet
Apo-Mirtazapine 30 mg Tablet0.73USD tablet
Mylan-Mirtazapine 30 mg Tablet0.73USD tablet
Novo-Mirtazapine 30 mg Tablet0.73USD tablet
Phl-Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 30 mg Tablet0.73USD tablet
Ratio-Mirtazapine 30 mg Tablet0.73USD tablet
Sandoz Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada23865472010-06-082020-10-09
United States51788781993-01-122010-01-12
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114-116 °CNot Available
water solubilitySlightNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.1 mg/mLALOGPS
logP2.9ALOGPS
logP3.21ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)6.67ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity82.66 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Leonid Metzger, “Methods for the preparation of mirtazapine intermediates.” U.S. Patent US20020165238, issued November 07, 2002.

US20020165238
General References
  1. Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. Pubmed
  2. Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. Pubmed
  3. Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. Pubmed
  4. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. Pubmed
  5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. Pubmed
  6. Pubmed
External Links
ATC CodesN06AX11
AHFS Codes
  • 28:16.04.92
PDB EntriesNot Available
FDA labelDownload (904 KB)
MSDSDownload (57.2 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Mirtazapine can be increased when it is combined with Abiraterone.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ApraclonidineMirtazapine may decrease the antihypertensive activities of Apraclonidine.
AprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AzelastineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BexaroteneThe serum concentration of Mirtazapine can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Mirtazapine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mirtazapine can be decreased when it is combined with Bosentan.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrimonidineMirtazapine may decrease the antihypertensive activities of Brimonidine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BuprenorphineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarbamazepineThe metabolism of Mirtazapine can be increased when combined with Carbamazepine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CitalopramMirtazapine may increase the QTc-prolonging activities of Citalopram.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClonidineMirtazapine may decrease the antihypertensive activities of Clonidine.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ConivaptanThe serum concentration of Mirtazapine can be increased when it is combined with Conivaptan.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Cyproterone acetateThe serum concentration of Mirtazapine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.
DasatinibThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Dexchlorpheniramine maleateDexchlorpheniramine maleate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DexmedetomidineMirtazapine may decrease the antihypertensive activities of Dexmedetomidine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DipivefrinMirtazapine may decrease the antihypertensive activities of Dipivefrin.
DofetilideMirtazapine may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluconazoleThe metabolism of Mirtazapine can be decreased when combined with Fluconazole.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluoxetineThe metabolism of Mirtazapine can be decreased when combined with Fluoxetine.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluvoxamineThe metabolism of Mirtazapine can be decreased when combined with Fluvoxamine.
FosaprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Mirtazapine can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
GoserelinMirtazapine may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Mirtazapine.
GuanfacineMirtazapine may decrease the antihypertensive activities of Guanfacine.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydrocodoneMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
IdelalisibThe serum concentration of Mirtazapine can be increased when it is combined with Idelalisib.
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Mirtazapine.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
IvacaftorThe serum concentration of Mirtazapine can be increased when it is combined with Ivacaftor.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Mirtazapine.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LeuprolideMirtazapine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LinezolidLinezolid may increase the serotonergic activities of Mirtazapine.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LuliconazoleThe serum concentration of Mirtazapine can be increased when it is combined with Luliconazole.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethotrimeprazineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethyldopaMirtazapine may decrease the antihypertensive activities of Methyldopa.
Methylene blueMirtazapine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metoclopramide.
MetyrosineMirtazapine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mirtazapine can be decreased when combined with Mexiletine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MifepristoneThe serum concentration of Mirtazapine can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Mirtazapine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the central neurotoxic activities of Mirtazapine.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NelfinavirThe metabolism of Mirtazapine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Mirtazapine can be increased when it is combined with Netupitant.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OrphenadrineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PalbociclibThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Mirtazapine can be increased when it is combined with Panobinostat.
ParaldehydeMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Peginterferon alfa-2bThe serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PhenelzinePhenelzine may increase the central neurotoxic activities of Mirtazapine.
PhenytoinThe metabolism of Mirtazapine can be increased when combined with Phenytoin.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PramipexoleMirtazapine may increase the sedative activities of Pramipexole.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ProcarbazineProcarbazine may increase the central neurotoxic activities of Mirtazapine.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RasagilineRasagiline may increase the central neurotoxic activities of Mirtazapine.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RitonavirThe metabolism of Mirtazapine can be decreased when combined with Ritonavir.
RopiniroleMirtazapine may increase the sedative activities of Ropinirole.
RotigotineMirtazapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mirtazapine.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Scopolamine butylbromideScopolamine butylbromide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SelegilineSelegiline may increase the central neurotoxic activities of Mirtazapine.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SiltuximabThe serum concentration of Mirtazapine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mirtazapine can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
St. John's WortThe serum concentration of Mirtazapine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mirtazapine can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SuvorexantMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Mirtazapine.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TeriflunomideThe serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.
ThalidomideMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TiclopidineThe metabolism of Mirtazapine can be decreased when combined with Ticlopidine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Mirtazapine.
TocilizumabThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mirtazapine.
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Mirtazapine.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
VemurafenibThe serum concentration of Mirtazapine can be increased when it is combined with Vemurafenib.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
WarfarinMirtazapine may increase the anticoagulant activities of Warfarin.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZolpidemMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

1. 5-hydroxytryptamine receptor 2A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. Pubmed
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. Pubmed
  3. Nutt DJ: Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. Pubmed
  4. Laakmann G, Schule C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 1999 Oct;24(7):769-84. Pubmed
  5. Waldinger MD, Berendsen HH, Schweitzer DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000 Oct 31;36(3):165-8. Pubmed
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Pubmed

2. 5-hydroxytryptamine receptor 3A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 3A P46098 Details

References:

  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. Pubmed
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. Pubmed
  3. Kast RE, Foley KF: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007 Jul;16(4):351-4. Pubmed
  4. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Pubmed

3. Alpha-2A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details

References:

  1. Garcia-Sevilla JA, Ventayol P, Perez V, Rubovszky G, Puigdemont D, Ferrer-Alcon M, Andreoli A, Guimon J, Alvarez E: Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology. 2004 Mar;29(3):580-8. Pubmed
  2. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Pubmed
  3. Besson A, Haddjeri N, Blier P, de Montigny C: Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 2000 May;10(3):177-88. Pubmed
  4. Schreiber S, Bleich A, Pick CG: Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects—a possible opioid involvement in severe depression? J Mol Neurosci. 2002 Feb-Apr;18(1-2):143-9. Pubmed
  5. Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol. 2002 Mar;53(1):105-16. Pubmed
  6. Rogoz Z, Wrobel A, Dlaboga D, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol. 2002 Jul-Aug;54(4):381-9. Pubmed

4. 5-hydroxytryptamine receptor 2C

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P28335 Details

References:

  1. Benelli A, Frigeri C, Bertolini A, Genedani S: Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology (Berl). 2004 Jan;171(3):250-8. Epub 2003 Nov 13. Pubmed
  2. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. Pubmed
  3. Meert TF, Melis W, Aerts N, Clincke G: Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol. 1997 Aug;8(4):353-63. Pubmed
  4. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. Pubmed
  5. Dekeyne A, Iob L, Millan MJ: Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology (Berl). 2001 Jan;153(3):389-92. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

5. Kappa-type opioid receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
Kappa-type opioid receptor P41145 Details

References:

  1. Schreiber S, Rigai T, Katz Y, Pick CG: The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull. 2002 Sep 30;58(6):601-5. Pubmed

6. Histamine H1 receptor

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Histamine H1 receptor P35367 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

7. Alpha-2C adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Alpha-2C adrenergic receptor P18825 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed
  3. Roth, BL; Driscol, J. “PDSD Ki Database”. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 2013-07-27.

8. 5-hydroxytryptamine receptor 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binding

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 7 P34969 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed
  3. Roth, BL; Driscol, J. “PDSD Ki Database”. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 2013-07-27.

9. Alpha-1 adrenergic receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details
Alpha-1B adrenergic receptor P35368 Details
Alpha-1D adrenergic receptor P25100 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman’s The Pharmacological Basis of Therapeutics (in English) (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed
  4. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. Pubmed

10. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. Pubmed
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed

11. D(3) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
D(3) dopamine receptor P35462 Details

References:

  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. Pubmed
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed

12. Sodium-dependent noradrenaline transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Sodium-dependent noradrenaline transporter P23975 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

13. Sodium-dependent serotonin transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Sodium-dependent serotonin transporter P31645 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

14. Sodium-dependent dopamine transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Sodium-dependent dopamine transporter Q01959 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

15. 5-hydroxytryptamine receptor 2B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2B P41595 Details

References:

  1. de Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25. Pubmed
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. Pubmed

16. D(1) dopamine receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details
D(1B) dopamine receptor P21918 Details

References:

  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed
  3. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. Pubmed
  4. Shaul Schreiber, Avi Bleich, and Chaim G. Pick. Venlafaxine and Mirtazapine. Journal of Molecular Neuroscience. 2002(18) 143-149

17. Histamine H3 receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Histamine H3 receptor Q9Y5N1 Details

References:

  1. Pytliak M, Vargova V, Mechirova V, Felsoci M: Serotonin receptors – from molecular biology to clinical applications. Physiol Res. 2011;60(1):15-25. Epub 2010 Oct 15. Pubmed
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. Pubmed
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. Pubmed
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. Pubmed

18. Alpha-1A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. Pubmed

19. Beta-1 adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Beta-1 adrenergic receptor P08588 Details

References:

  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. Pubmed

20. Beta-2 adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Beta-2 adrenergic receptor P07550 Details

References:

  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. Pubmed

2. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. Pubmed

3. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. Pubmed

4. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 19, 2014 10:09